Cargando…

Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization

PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolizat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Yanqiao, Dong, Xiangjun, Chen, Lei, Sun, Tao, Alwalid, Osamah, Kan, Xuefeng, Su, Yangbo, Xiong, Bin, Liang, Huimin, Zheng, Chuansheng, Han, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961082/
https://www.ncbi.nlm.nih.gov/pubmed/33738247
http://dx.doi.org/10.3389/fonc.2021.582544
_version_ 1783665180479062016
author Ren, Yanqiao
Dong, Xiangjun
Chen, Lei
Sun, Tao
Alwalid, Osamah
Kan, Xuefeng
Su, Yangbo
Xiong, Bin
Liang, Huimin
Zheng, Chuansheng
Han, Ping
author_facet Ren, Yanqiao
Dong, Xiangjun
Chen, Lei
Sun, Tao
Alwalid, Osamah
Kan, Xuefeng
Su, Yangbo
Xiong, Bin
Liang, Huimin
Zheng, Chuansheng
Han, Ping
author_sort Ren, Yanqiao
collection PubMed
description PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolization (TACE). METHODS: This retrospective study analyzed the consecutive medical records of 31 HCC patients with residual tumors located at complex sites (such as large blood vessels, gallbladder, diaphragm dome, etc.) after TACE from May 2014 to December 2018, all of whom received (125)I seeds implantation therapy. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were documented. RESULTS: A total of 607 seeds were implanted in 31 patients, with an average of 19.6±10.4 (range, 8–48) seeds per patient. Median OS and PFS were 33 months (95% CI: 27.1 months, 38.9 months) and 15 months (95% CI: 9.6 months, 20.4 months), respectively. Although univariate analysis showed that albumin, prothrombin time, alpha-fetoprotein level, Child-Pugh score, and lipiodol deposition in tumor were associated with OS, multivariate analysis showed that none of them was an independent prognostic factor for OS. Multivariate analysis showed that prothrombin time was an independent prognostic factor for PFS. No operation-related deaths in this study. Although pneumothorax was present in two patients and subcutaneous abscess in one patient, symptoms improved in all three patients with appropriate treatment. Common minor complications included fever, abdominal pain and leukopenia and no grade≥3 adverse events were observed. CONCLUSIONS: (125)I seeds implantation under the combined guidance of ultrasound and CT is safe and effective for patients with residual HCC located at complex sites after TACE. This is a promising treatment approach and deserves further discussion.
format Online
Article
Text
id pubmed-7961082
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79610822021-03-17 Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization Ren, Yanqiao Dong, Xiangjun Chen, Lei Sun, Tao Alwalid, Osamah Kan, Xuefeng Su, Yangbo Xiong, Bin Liang, Huimin Zheng, Chuansheng Han, Ping Front Oncol Oncology PURPOSE: The purpose of this study was to evaluate the efficacy and safety of iodine-125 ((125)I) seeds implantation under ultrasound and computed tomography (CT) guidance in the treatment of residual hepatocellular carcinoma (HCC) located at complex sites after transcatheter arterial chemoembolization (TACE). METHODS: This retrospective study analyzed the consecutive medical records of 31 HCC patients with residual tumors located at complex sites (such as large blood vessels, gallbladder, diaphragm dome, etc.) after TACE from May 2014 to December 2018, all of whom received (125)I seeds implantation therapy. Overall survival (OS), progression-free survival (PFS), recurrence, and complications were documented. RESULTS: A total of 607 seeds were implanted in 31 patients, with an average of 19.6±10.4 (range, 8–48) seeds per patient. Median OS and PFS were 33 months (95% CI: 27.1 months, 38.9 months) and 15 months (95% CI: 9.6 months, 20.4 months), respectively. Although univariate analysis showed that albumin, prothrombin time, alpha-fetoprotein level, Child-Pugh score, and lipiodol deposition in tumor were associated with OS, multivariate analysis showed that none of them was an independent prognostic factor for OS. Multivariate analysis showed that prothrombin time was an independent prognostic factor for PFS. No operation-related deaths in this study. Although pneumothorax was present in two patients and subcutaneous abscess in one patient, symptoms improved in all three patients with appropriate treatment. Common minor complications included fever, abdominal pain and leukopenia and no grade≥3 adverse events were observed. CONCLUSIONS: (125)I seeds implantation under the combined guidance of ultrasound and CT is safe and effective for patients with residual HCC located at complex sites after TACE. This is a promising treatment approach and deserves further discussion. Frontiers Media S.A. 2021-03-02 /pmc/articles/PMC7961082/ /pubmed/33738247 http://dx.doi.org/10.3389/fonc.2021.582544 Text en Copyright © 2021 Ren, Dong, Chen, Sun, Alwalid, Kan, Su, Xiong, Liang, Zheng and Han http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Ren, Yanqiao
Dong, Xiangjun
Chen, Lei
Sun, Tao
Alwalid, Osamah
Kan, Xuefeng
Su, Yangbo
Xiong, Bin
Liang, Huimin
Zheng, Chuansheng
Han, Ping
Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title_full Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title_fullStr Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title_full_unstemmed Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title_short Combined Ultrasound and CT-Guided Iodine-125 Seeds Implantation for Treatment of Residual Hepatocellular Carcinoma Located at Complex Sites After Transcatheter Arterial Chemoembolization
title_sort combined ultrasound and ct-guided iodine-125 seeds implantation for treatment of residual hepatocellular carcinoma located at complex sites after transcatheter arterial chemoembolization
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7961082/
https://www.ncbi.nlm.nih.gov/pubmed/33738247
http://dx.doi.org/10.3389/fonc.2021.582544
work_keys_str_mv AT renyanqiao combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT dongxiangjun combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT chenlei combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT suntao combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT alwalidosamah combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT kanxuefeng combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT suyangbo combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT xiongbin combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT lianghuimin combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT zhengchuansheng combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization
AT hanping combinedultrasoundandctguidediodine125seedsimplantationfortreatmentofresidualhepatocellularcarcinomalocatedatcomplexsitesaftertranscatheterarterialchemoembolization